Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations. Issue 5 (4th May 2017)

• Record Type: Journal Article
• Authors: Korfi, Koorosh; Ali, Sara; Heward, James A.; Fitzgibbon, Jude
• Is Part Of: Epigenetics. Volume 12:Issue 5(2017)
• Page Start: 370
• Page End: 377
• Publication Date: 2017-05-04
• Subjects: Epigenetic mutations -- epigenetic therapies -- EZH2 inhibitors -- follicular lymphoma -- HDAC inhibitors; Epigenesis -- Periodicals; Epigenetica; 572.86505
• DOI: 10.1080/15592294.2017.1282587
• Languages: English
• ISSNs: 1559-2294

Abstract

ABSTRACT: While follicular lymphoma (FL) is exquisitely responsive to immuno-chemotherapy, many patients follow a relapsing remitting clinical course driven in part by a common precursor cell (CPC) population. Advances in next generation sequencing have provided valuable insights into the genetic landscape of FL and its clonal evolution in response to therapy, implicating perturbations of epigenetic regulators as a hallmark of the disease. Recurrent mutations of histone modifiers KMT2D, CREBBP, EP300, EZH2, ARIDIA, and linker histones are likely early events arising in the CPC pool, rendering epigenetic based therapies conceptually attractive for treatment of indolent and transformed FL. This review provides a synopsis of the main epigenetic aberrations and the current efforts in development and testing of epigenetic therapies in this B cell malignancy.